OptiNose, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022
March 08, 2022 at 07:01 am EST
Share
OptiNose, Inc. provided revenue guidance for the first quarter and full year of 2022. The Company's expectation that first quarter 2022 XHANCE net revenue will decrease compared to fourth quarter 2021. The primary driver of the sequential decrease to revenue is the Company's expectation that XHANCE average net revenue per prescription for the first quarter of 2022 will decrease, due to typical early-year effects on price and volume related to patient insurance that the Company believes are common for chronic treatments that derive a significant proportion of total prescriptions from refills.
For full year, the Company expects XHANCE net revenues for the full year of 2022 to be at least $90 million. In addition, the Company expects XHANCE average net revenue per prescription to exceed $210 for full year 2022.
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
OPTINOSE, INC. 
